Tryptase, a protease produced by all mast cells, was evaluated as a clinical marker of systemic mastocytosis. Two sandwich immunoassays were evaluated, one which used the mAb G5 for capture, the other which used B12 for capture. The B12 capture assay measured both recombinant alpha- and beta-tryptase, whereas the G5 capture assay measured primarily recombinant beta-tryptase. G5 binds with low affinity to both recombinant alpha-tryptase and tryptase in blood from normal and nonacute mastocytosis subjects, and binds with high affinity to recombinant beta-tryptase, tryptase in serum during anaphylaxis, and tryptase stored in mast cell secretory granules. B12 recognizes all of these forms of tryptase with high affinity. As reported previously, during systemic anaphylaxis in patients without known mastocytosis, the ratio of B12- to G5-measured tryptase was always < 5 and approached unity (Schwartz L.B., T.R. Bradford, C. Rouse, A.-M. Irani, G. Rasp, J.K. Van der Zwan and P.-W.G. Van der Linden, J. Clin. Immunol. 14:190-204). In this report, most mastocytosis patients with systemic disease have B12-measured tryptase levels that are elevated (> 20 ng/ml) and are at least 10-fold greater than the corresponding G5-measured tryptase level. Most of those subjects with B12-measured tryptase levels of < 20 ng/ml had only cutaneous manifestations. The B12 assay for alpha-tryptase and beta-tryptase, particularly when performed in conjunction with the G5 assay for beta-tryptase, provides a more precise measure of mast cell involvement than currently available assessments, a promising potential screening test for systemic mastocytosis and may provide an improved means to follow disease progression and response to therapy.
L B Schwartz, K Sakai, T R Bradford, S Ren, B Zweiman, A S Worobec, D D Metcalfe
Title and authors | Publication | Year |
---|---|---|
Anaphylaxis as a Clinical Manifestation of Clonal Mast Cell Disorders
A Matito, I Alvarez-Twose, JM Morgado, L Sánchez-Muñoz, A Orfao, L Escribano |
Current Allergy and Asthma Reports | 2014 |
A Brief Exposure to Tryptase or Thrombin Potentiates Fibrocyte Differentiation in the Presence of Serum or Serum Amyloid P
MJ White, E Galvis-Carvajal, RH Gomer |
Journal of immunology (Baltimore, Md. : 1950) | 2014 |
Mastocytosis
MC Carter, DD Metcalfe, HD Komarow |
Immunology and Allergy Clinics of North America | 2014 |
Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders
P Valent |
Clinical & Experimental Allergy | 2014 |
Perioperative Anaphylaxis
VR Galvão, P Giavina-Bianchi, M Castells |
Current Allergy and Asthma Reports | 2014 |
The serum tryptase test: an emerging robust biomarker in clinical hematology
P Valent, WR Sperr, K Sotlar, A Reiter, C Akin, J Gotlib, HP Horny, M Arock |
Expert Review of Hematology | 2014 |
Diagnosis and Treatment of Anaphylaxis in Patients with Mastocytosis
P Valent, C Akin, M Arock |
Current Treatment Options in Allergy | 2014 |
Diagnostic Criteria and Classification of Mastocytosis in 2014
C Akin, P Valent |
Immunology and Allergy Clinics of North America | 2014 |
Disease spectrum in patients with elevated serum tryptase levels: Elevated tryptase in skin disease
E Aberer, S Savic, A Bretterklieber, H Reiter, A Berghold, W Aberer |
Australasian Journal of Dermatology | 2014 |
Myeloproliferative Disorders
B Meier, JH Burton |
Emergency Medicine Clinics of North America | 2014 |
Diagnostic Value of Histamine and Tryptase Concentrations in Severe Anaphylaxis with Shock or Cardiac Arrest during Anesthesia:
D Laroche, P Gomis, E Gallimidi, JM Malinovsky, PM Mertes |
Anesthesiology | 2014 |
Does β-Hexosaminidase Function Only as a Degranulation Indicator in Mast Cells? The Primary Role of β-Hexosaminidase in Mast Cell Granules
N Fukuishi, S Murakami, A Ohno, N Yamanaka, N Matsui, K Fukutsuji, S Yamada, K Itoh, M Akagi |
Journal of immunology (Baltimore, Md. : 1950) | 2014 |
Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia
S Cerny-Reiterer, A Rabenhorst, G Stefanzl, S Herndlhofer, G Hoermann, L Müllauer, S Baumgartner, C Beham-Schmid, WR Sperr, C Mannhalter, H Sill, W Linkesch, M Arock, K Hartmann, P Valent |
Oncotarget | 2014 |